Logo image of ZYBT

ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) Stock Fundamental Analysis

NASDAQ:ZYBT - Nasdaq - KYG989MS1016 - Common Stock - Currency: USD

10.06  +2.44 (+32.02%)

After market: 10.6 +0.54 (+5.37%)

Fundamental Rating

3

ZYBT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 197 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ZYBT get a neutral evaluation. Nothing too spectacular is happening here. ZYBT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year ZYBT has reported negative net income.
In the past year ZYBT had a positive cash flow from operations.
ZYBT Yearly Net Income VS EBIT VS OCF VS FCFZYBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 20K 40K 60K

1.2 Ratios

ZYBT's Return On Assets of 12.63% is amongst the best of the industry. ZYBT outperforms 95.43% of its industry peers.
ZYBT has a Return On Equity of 21.87%. This is amongst the best in the industry. ZYBT outperforms 94.42% of its industry peers.
Looking at the Return On Invested Capital, with a value of 21.98%, ZYBT belongs to the top of the industry, outperforming 95.94% of the companies in the same industry.
ZYBT had an Average Return On Invested Capital over the past 3 years of 14.62%. This is significantly below the industry average of 40.40%.
The 3 year average ROIC (14.62%) for ZYBT is below the current ROIC(21.98%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.63%
ROE 21.87%
ROIC 21.98%
ROA(3y)9.55%
ROA(5y)N/A
ROE(3y)16.64%
ROE(5y)N/A
ROIC(3y)14.62%
ROIC(5y)N/A
ZYBT Yearly ROA, ROE, ROICZYBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 5 10 15

1.3 Margins

ZYBT's Profit Margin of 18.75% is amongst the best of the industry. ZYBT outperforms 92.39% of its industry peers.
ZYBT has a Operating Margin of 27.12%. This is amongst the best in the industry. ZYBT outperforms 92.89% of its industry peers.
ZYBT's Gross Margin of 61.59% is fine compared to the rest of the industry. ZYBT outperforms 70.05% of its industry peers.
Industry RankSector Rank
OM 27.12%
PM (TTM) 18.75%
GM 61.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYBT Yearly Profit, Operating, Gross MarginsZYBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 20 40 60

More info and screens

6

2. Health

2.1 Basic Checks

ZYBT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, ZYBT has about the same amount of shares outstanding.
The debt/assets ratio for ZYBT is higher compared to a year ago.
ZYBT Yearly Shares OutstandingZYBT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M 40M
ZYBT Yearly Total Debt VS Total AssetsZYBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 100K 200K 300K 400K 500K

2.2 Solvency

An Altman-Z score of 10087.75 indicates that ZYBT is not in any danger for bankruptcy at the moment.
The Altman-Z score of ZYBT (10087.75) is better than 100.00% of its industry peers.
There is no outstanding debt for ZYBT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 3.05
Altman-Z 10087.75
ROIC/WACC2.67
WACC8.24%
ZYBT Yearly LT Debt VS Equity VS FCFZYBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 100K 200K

2.3 Liquidity

A Current Ratio of 1.38 indicates that ZYBT should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.38, ZYBT is doing worse than 75.13% of the companies in the same industry.
A Quick Ratio of 0.91 indicates that ZYBT may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.91, ZYBT is doing worse than 79.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 0.91
ZYBT Yearly Current Assets VS Current LiabilitesZYBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50K 100K 150K 200K

More info and screens

0

3. Growth

3.1 Past

ZYBT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.33%.
ZYBT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.67%.
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-18.67%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYBT Yearly Revenue VS EstimatesZYBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 50K 100K 150K 200K 250K

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYBT Price Earnings VS Forward Price EarningsZYBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ZYBT indicates a somewhat cheap valuation: ZYBT is cheaper than 74.62% of the companies listed in the same industry.
75.63% of the companies in the same industry are more expensive than ZYBT, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 120658.51
EV/EBITDA 30809.42
ZYBT Per share dataZYBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0 0 0 0

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZYBT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZHENGYE BIOTECHNOLOGY HOLDIN

NASDAQ:ZYBT (4/17/2025, 8:00:02 PM)

After market: 10.6 +0.54 (+5.37%)

10.06

+2.44 (+32.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners6.83%
Ins Owner ChangeN/A
Market Cap474.53M
AnalystsN/A
Price TargetN/A
Short Float %0.87%
Short Ratio0.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP-67.53%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10538.35
P/FCF 120658.51
P/OCF 62961.97
P/B 12297.23
P/tB 13067.55
EV/EBITDA 30809.42
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFY0%
OCF(TTM)0
OCFY0%
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.63%
ROE 21.87%
ROCE 25.44%
ROIC 21.98%
ROICexc 22.53%
ROICexgc 23.68%
OM 27.12%
PM (TTM) 18.75%
GM 61.59%
FCFM 8.73%
ROA(3y)9.55%
ROA(5y)N/A
ROE(3y)16.64%
ROE(5y)N/A
ROIC(3y)14.62%
ROIC(5y)N/A
ROICexc(3y)15.08%
ROICexc(5y)N/A
ROICexgc(3y)15.83%
ROICexgc(5y)N/A
ROCE(3y)16.92%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 3.05
Debt/EBITDA 0
Cap/Depr 112.88%
Cap/Sales 8%
Interest Coverage 20.72
Cash Conversion 48.93%
Profit Quality 46.59%
Current Ratio 1.38
Quick Ratio 0.91
Altman-Z 10087.75
F-Score7
WACC8.24%
ROIC/WACC2.67
Cap/Depr(3y)119.58%
Cap/Depr(5y)N/A
Cap/Sales(3y)9.43%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-18.67%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y466%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y178.61%
OCF growth 3YN/A
OCF growth 5YN/A